Cigna Reports Material Agreement & New Financial Obligation

TL;DR

**Cigna filed an 8-K on Feb 13, reporting a new material agreement and financial obligation, but specific details are missing.**

AI Summary

The Cigna Group filed an 8-K on February 13, 2024, reporting the entry into a Material Definitive Agreement and the creation of a Direct Financial Obligation. The filing also included Regulation FD Disclosure and other events. Specific details regarding the nature, terms, or parties involved in these agreements or obligations were not provided in this initial section of the document.

Why It Matters

The disclosure of a Material Definitive Agreement and a Direct Financial Obligation indicates significant corporate actions that could impact Cigna Group's financial position and future operations, though specific details are not yet available to assess the full impact.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement and a direct financial obligation, which could significantly impact the company, but specific terms are not disclosed, making the exact risk profile unknown.

Key Players & Entities

• Cigna Group (company) — registrant
• Cigna Corp (company) — former name of registrant
• Halfmoon Parent, Inc. (company) — former name of registrant

FAQ

From the Filing

0001140361-24-007429.txt : 20240213 0001140361-24-007429.hdr.sgml : 20240213 20240213160645 ACCESSION NUMBER: 0001140361-24-007429 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240213 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240213 DATE AS OF CHANGE: 20240213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cigna Group CENTRAL INDEX KEY: 0001739940 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] ORGANIZATION NAME: 02 Finance IRS NUMBER: 824991898 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38769 FILM NUMBER: 24625806 BUSINESS ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 BUSINESS PHONE: 8602266000 MAIL ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 FORMER COMPANY: FORMER CONFORMED NAME: Cigna Corp DATE OF NAME CHANGE: 20181221 FORMER COMPANY: FORMER CONFORMED NAME: Halfmoon Parent, Inc. DATE OF NAME CHANGE: 20180508 8-K 1 ny20020170x6_8k.htm 8-K false 0001739940 NYSE 0001739940 2024-02-13 2024-02-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991898 (IRS Employer Identification No.) 900 Cottage Grove Road Bloomfield , Connecticut 06002 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: ( 860 ) 226-6000 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $0.01 CI New York Stock Exchange, Inc. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR Sec.230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR Sec.240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01 Entry into a Material Definitive Agreement. On February 13, 2024, The Cigna Group (the “Company” or “our”) completed its previously announced offering of $1.0 billion in aggregate principal amount of its 5.000% Senior Notes due 2029 (the “2029 Notes”), $750 million in aggregate principal amount of its 5.125% Senior Notes due 2031 (the “2031 Notes”), $1.25 billion in aggregate principal amount of its 5.250% Senior Notes due 2034 (the “2034 Notes”) and $1.5 billion in aggregate principal amount of its 5.600